Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report
{{output}}
Background: Fibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rar... ...
